Complement 3 is involved in changing the phenotype of human glomerular mesangial cells. 2007

Jian-Xin Wan, and Noboru Fukuda, and Morito Endo, and Yoshiko Tahira, and En-Hui Yao, and Hiroyuki Matsuda, and Takahiro Ueno, and Koichi Matsumoto
Department of Medicine, Division of Nephrology and Endocrinology, Nihon University School of Medicine, Tokyo, Japan.

Complement activation contributes to tissue injury in various forms of glomerulopathy and is characterized by deposition of complement components, which accelerates the progression of chronic renal damage. We recently reported that complement 3 (C3), a critical component of the complement system, is associated with the synthetic phenotype of vascular smooth muscle cells. It is possible that C3 stimulates mesangial cells to assume the synthetic phenotype to, in turn, induce glomerular injury and sclerosis. We investigated the role of C3 in the growth and phenotype of mesangial cells. Cultured human mesangial cells (HMCs) expressed C3 mRNA and protein, and levels were increased in response to IFN-gamma and TNF-alpha. HMCs also expressed C3a receptor mRNA and protein. Exogenous C3a stimulated DNA synthesis in HMCs in a dose-dependent manner. C3a decreased expression h-caldesmon mRNA, a marker of the contractile phenotype, and increased the expression of osteopontin, matrix Gla, and collagen type1 alpha1 (collagen IV) mRNAs, which are markers of the synthetic phenotype. C3a decreased expression of alpha-smooth muscle actin in HMCs. Small interfering RNA (siRNA) targeting C3 reduced the DNA synthesis and proliferation of HMCs, increased expression of h-caldesmon mRNA, and decreased expression of osteopontin, matrix Gla, and collagen IV mRNAs in HMCs. These results indicate that C3 causes HMCs to convert to the synthetic phenotype and stimulates growth of mesangial cells, suggesting that C3 may play an important role in phenotypic regulation of mesangial cells in renal diseases.

UI MeSH Term Description Entries
D007155 Immunologic Factors Biologically active substances whose activities affect or play a role in the functioning of the immune system. Biological Response Modifier,Biomodulator,Immune Factor,Immunological Factor,Immunomodulator,Immunomodulators,Biological Response Modifiers,Biomodulators,Factors, Immunologic,Immune Factors,Immunological Factors,Modifiers, Biological Response,Response Modifiers, Biological,Factor, Immune,Factor, Immunological,Factors, Immune,Factors, Immunological,Modifier, Biological Response,Response Modifier, Biological
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D011951 Receptors, Complement Molecules on the surface of some B-lymphocytes and macrophages, that recognize and combine with the C3b, C3d, C1q, and C4b components of complement. Complement Receptors,Complement Receptor,Complement Receptor Type 1,Receptor, Complement
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D003176 Complement C3 A glycoprotein that is central in both the classical and the alternative pathway of COMPLEMENT ACTIVATION. C3 can be cleaved into COMPLEMENT C3A and COMPLEMENT C3B, spontaneously at low level or by C3 CONVERTASE at high level. The smaller fragment C3a is an ANAPHYLATOXIN and mediator of local inflammatory process. The larger fragment C3b binds with C3 convertase to form C5 convertase. C3 Complement,C3 Precursor,Complement 3,Complement C3 Precursor,Complement Component 3,Precursor-Complement 3,Pro-C3,Pro-Complement 3,C3 Precursor, Complement,C3, Complement,Complement, C3,Component 3, Complement,Precursor Complement 3,Precursor, C3,Precursor, Complement C3,Pro C3,Pro Complement 3
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014409 Tumor Necrosis Factor-alpha Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS. Cachectin,TNF-alpha,Tumor Necrosis Factor Ligand Superfamily Member 2,Cachectin-Tumor Necrosis Factor,TNF Superfamily, Member 2,TNFalpha,Tumor Necrosis Factor,Cachectin Tumor Necrosis Factor,Tumor Necrosis Factor alpha
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune

Related Publications

Jian-Xin Wan, and Noboru Fukuda, and Morito Endo, and Yoshiko Tahira, and En-Hui Yao, and Hiroyuki Matsuda, and Takahiro Ueno, and Koichi Matsumoto
January 2001, Kidney international,
Jian-Xin Wan, and Noboru Fukuda, and Morito Endo, and Yoshiko Tahira, and En-Hui Yao, and Hiroyuki Matsuda, and Takahiro Ueno, and Koichi Matsumoto
January 2022, Hypertension research : official journal of the Japanese Society of Hypertension,
Jian-Xin Wan, and Noboru Fukuda, and Morito Endo, and Yoshiko Tahira, and En-Hui Yao, and Hiroyuki Matsuda, and Takahiro Ueno, and Koichi Matsumoto
April 1996, The American journal of physiology,
Jian-Xin Wan, and Noboru Fukuda, and Morito Endo, and Yoshiko Tahira, and En-Hui Yao, and Hiroyuki Matsuda, and Takahiro Ueno, and Koichi Matsumoto
January 1994, Experimental nephrology,
Jian-Xin Wan, and Noboru Fukuda, and Morito Endo, and Yoshiko Tahira, and En-Hui Yao, and Hiroyuki Matsuda, and Takahiro Ueno, and Koichi Matsumoto
September 2017, The Korean journal of internal medicine,
Jian-Xin Wan, and Noboru Fukuda, and Morito Endo, and Yoshiko Tahira, and En-Hui Yao, and Hiroyuki Matsuda, and Takahiro Ueno, and Koichi Matsumoto
January 2003, Contributions to nephrology,
Jian-Xin Wan, and Noboru Fukuda, and Morito Endo, and Yoshiko Tahira, and En-Hui Yao, and Hiroyuki Matsuda, and Takahiro Ueno, and Koichi Matsumoto
May 2007, Journal of the American Society of Nephrology : JASN,
Jian-Xin Wan, and Noboru Fukuda, and Morito Endo, and Yoshiko Tahira, and En-Hui Yao, and Hiroyuki Matsuda, and Takahiro Ueno, and Koichi Matsumoto
January 1991, International archives of allergy and applied immunology,
Jian-Xin Wan, and Noboru Fukuda, and Morito Endo, and Yoshiko Tahira, and En-Hui Yao, and Hiroyuki Matsuda, and Takahiro Ueno, and Koichi Matsumoto
February 1976, Laboratory investigation; a journal of technical methods and pathology,
Jian-Xin Wan, and Noboru Fukuda, and Morito Endo, and Yoshiko Tahira, and En-Hui Yao, and Hiroyuki Matsuda, and Takahiro Ueno, and Koichi Matsumoto
April 1995, Experientia,
Copied contents to your clipboard!